Navigation Links
Abbott's XIENCE V(R) Demonstrates Significantly Lower Rates of MACE and Stent Thrombosis Compared to TAXUS(R) Liberte in Investigator-Initiated COMPARE Trial
Date:9/23/2009

SAN FRANCISCO, Sept. 23 /PRNewswire-FirstCall/ -- Late-breaking data presented today from the COMPARE trial demonstrated that Abbott's (NYSE: ABT) market-leading XIENCE V(R) Everolimus Eluting Coronary Stent System demonstrated significantly better outcomes in key safety and efficacy measures compared to the TAXUS(R) Liberte Paclitaxel-Eluting Coronary Stent System (TAXUS). At one year, XIENCE V demonstrated a significantly lower incidence of major adverse cardiac events (MACE) compared to TAXUS (6.2% XIENCE V vs. 9.1% TAXUS, p-value= 0.023) in the trial's primary endpoint, which is a composite of all death, non-fatal heart attack (myocardial infarction) and target vessel revascularization (TVR). Additionally, XIENCE V demonstrated a significantly lower rate of stent thrombosis compared to TAXUS (0.7% XIENCE V vs. 2.6% TAXUS, p-value=0.002), a significantly lower rate of TVR (2.4% XIENCE V vs. 6.0% TAXUS, p-value=0.0001), and a significantly lower rate of TLR (1.7% XIENCE V vs. 4.8% TAXUS, p-value=0.0002).

The results from the COMPARE trial were presented by Peter Smits, M.D., of Maasstad Ziekenhuis, Rotterdam, the Netherlands, during the 2009 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco.

"The COMPARE trial, which studied a real-world, complex patient population, reaffirms what we saw in SPIRIT IV earlier today and what we've seen throughout our SPIRIT family of trials - with XIENCE V showing consistent, outstanding performance compared to TAXUS, whether it's TAXUS Express in SPIRIT IV or now TAXUS Liberte in the investigator-initiated study COMPARE," said John Capek, Ph.D., executive vice president, Medical Devices, Abbott.

About XIENCE V

XIENCE V is used to treat coronary artery disease by propping ope
'/>"/>

SOURCE Abbott
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Abbotts XIENCE V(R) Superior to TAXUS(R) in Key Safety and Efficacy Measures in SPIRIT IV Trial
2. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
3. Abbotts Market-Leading XIENCE V(R) Shows Increasing Clinical Advantages Over TAXUS(R) Express2(TM)/TAXUS(R) Liberte(TM) Between Two and Three Years
4. Circulation Publishes Pivotal Two-Year Results On XIENCE V(TM) Drug Eluting Stent
5. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
6. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
7. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
8. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
9. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
10. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
11. MoxDuo(TM) IR Demonstrates Fewer Side Effects Than Percocet(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...   Sigma-Aldrich Corporation (NASDAQ: SIAL ) a ... a $50,000 product donation to the Reproducibility Project: ... findings from recent high-impact papers in the field of ... online research marketplace Science Exchange , the non-profit ... journal eLife. The goal of the project ...
(Date:5/6/2015)... May 6, 2015 AbbVie (NYSE: ABBV ... Lynch 2015 Health Care Conference on Wednesday, May 13, ... executive officer, will participate in a question and answer ... live audio webcast of the presentation will be accessible ... .  An archived edition of the session will be ...
(Date:5/6/2015)... Pharmaceuticals, Inc. (Nasdaq: JNP ) ("Juniper" or the ... ended March 31, 2015. First quarter financial highlights include: ... 19% as compared to $7.0 million in the first ... year-over-year, enabled by the return of normalized CRINONE ® ... fourth quarter of 2014; , Service revenues grew ...
Breaking Medicine Technology:Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 2Sigma-Aldrich Donates $50K in Products to the Reproducibility Project to Foster Replicable Research and Accelerate Scientific Discoveries in Cancer Biology 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 2Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 3Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 4Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 5Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 6Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 7Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 8Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 9Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 10Juniper Pharmaceuticals Reports First Quarter 2015 Financial Results 11
... Mass. and SYDNEY, Nov. 4 HeartWare International, Inc. ... and provider of less invasive, miniaturized circulatory support technologies ... a significant increase in revenues to $7.5 million for ... to approximately $3.0 million in revenues in the second ...
... 4 Sanford Wittels & Heisler, LLP, along with ... medical device company specializing in cardiac surgical ablation systems, ... of Justice (DOJ) in a qui tam case filed ... five-year period. , Sanford Wittels & Heisler and Grant ...
Cached Medicine Technology:HeartWare International Reports Third Quarter Revenues of $7.5 Million 2HeartWare International Reports Third Quarter Revenues of $7.5 Million 3HeartWare International Reports Third Quarter Revenues of $7.5 Million 4HeartWare International Reports Third Quarter Revenues of $7.5 Million 5HeartWare International Reports Third Quarter Revenues of $7.5 Million 6HeartWare International Reports Third Quarter Revenues of $7.5 Million 7Relator's Attorneys Comment On AtriCure/DOJ Proposed Settlement 2
(Date:5/6/2015)... 06, 2015 The Center for Innovative ... has invested in e-Kare, Inc. of Fairfax, VA, a ... monitoring of chronic wounds. , Chronic wounds include pressure, ... wounds that affect over 6.5 million U.S. patients, costing ... spin-off enterprise from the Children’s National Medical Center (CNMC), ...
(Date:5/6/2015)... Aliso Viejo, CA (PRWEB) May 06, 2015 ... of unique and fun self-animating generators for Final ... users to add stylistic titles to a Final Cut ... unique environments, adding professional quality openers to any shot ... for any skill level in mind, saving users time ...
(Date:5/6/2015)... 06, 2015 Healthcare marketing agency ... a silver award in the 2015 Aster Awards for ... and Ellis Medicine’s maternity campaign, respectively. The Aster Awards ... organizations and marketing agencies. , The branding campaign ... line — other/misc. category and hospital 150-200 bed group. ...
(Date:5/6/2015)... 2015 The SGNY Group LLC (SGNY), ... announced today that it was named a Platinum winner ... video produced on behalf of Intarcia Therapeutics. SGNY ... motion graphics. , The competition sponsored by the Association ... entries from 22 countries. The competition is an ...
(Date:5/6/2015)... 2015 The beverage industry has grocery ... Miracles organic tea and superfruit fusions stands out among ... sweetened with agave, these delicious juice blends are making ... healthier ways to hydrate. , In collaboration with National ... to raise a bottle of Lemongrass Tea and Ginseng, ...
Breaking Medicine News(10 mins):Health News:CIT GAP Funds Invests in e-Kare 2Health News:CIT GAP Funds Invests in e-Kare 3Health News:Pixel Film Studios announces the release of Protrailer Cartoon Volume 2 for Final Cut Pro X. 2Health News:Smith & Jones Wins in 2015 Aster Awards for Healthcare Marketing 2Health News:The SGNY Group Wins Platinum Hermes Creative Award 2Health News:Say Cheers to National Beverage Day with Little Miracles 2
... The ,Help is Here Express, bus tour will ... 13 -- April 17 at various cities in order ... programs that provide prescription medicines for free or nearly ... percent, the Partnership for Prescription Assistance (PPA) is ready ...
... a new procedure for regenerating damaged articular cartilage in ... Rush is the only center in Illinois participating ... procedure, called the Cartilage Autograft Implantation System (CAIS), involves ... the knee, breaking it into tiny fragments to enable ...
... a neurobiological condition which is often responsive to Applied ... fail to provide this medically necessary service to their ... as the Mental Health Parity Act, has been on ... obliges private health insurance companies to offer treatment services ...
... of residue, study finds , , THURSDAY, April 9 (HealthDay News) ... do not smoke have elevated levels of the residue of ... , And that suggests that nonsmokers in the city -- ... are not adequately protected from cigarette smoke, it says. , ...
... FREE TO THE PUBLICPanel Discussion To Follow With Local ... A free screening of HBO Documentary Films, THE ... at The Neurosciences Institute (10640 John Jay Hopkins Dr.) ... 6:00pm. Following the film, Hal Clement, anchor-reporter with 10News ...
... two-decade surge of legalized gambling is chipping away at ... accounts of bettors, a comprehensive new collection of research ... money from consumer products and services, weakening the economic ... latest volume in the three-part United States International Gambling ...
Cached Medicine News:Health News:Partnership for Prescription Assistance Prepared to Help Arkansas Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Arkansas Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Arkansas Workers Hurt by Recession 4Health News:Study assesses new surgical procedure for regenerating cartilage in damaged knee joints 2Health News:Uncovering the Secrets of Getting California Health Insurance to Pay for Autism Treatments 2Health News:Uncovering the Secrets of Getting California Health Insurance to Pay for Autism Treatments 3Health News:Secondhand Smoke Affecting Millions of New Yorkers 2Health News:HBO, UCSD Shiley-Marcos Alzheimer's Disease Research Center, The Alzheimer's Association San Diego/Imperial Chapter and The Neurosciences Institute Present an Advance Screening of THE ALZHEIMER'S PROJECT: 'MOMENTUM IN SCIENCE' 2Health News:Gambling threatens national security, new book warns 2
... Our ELISA products for autoimmune testing feature ... as well as specific reflex tests including ... Sm/RNP, SS-A (Ro), SS-B (La), Scl-70 and ... includes a full line of products for ...
... ELISA products for autoimmune testing feature single-well ... well as specific reflex tests including dsDNA, ... SS-A (Ro), SS-B (La), Scl-70 and Jo-1. ... a full line of products for Cardiolipins ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: